NCT00349830

Brief Summary

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
68mo left

Started Jan 2002

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Jan 2002Jan 2032

Study Start

First participant enrolled

January 1, 2002

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

July 5, 2006

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 10, 2006

Completed
25.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2032

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2032

Last Updated

February 10, 2026

Status Verified

February 1, 2026

Enrollment Period

30 years

First QC Date

July 5, 2006

Last Update Submit

February 7, 2026

Conditions

Carcinomas (Including Squamous Cell and Adenocarcinoma)Neoplasms

Outcome Measures

Primary Outcomes (1)

  • Biomarkers for disease

    Day one

Interventions

blood drawPROCEDURE

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

cancer patients

1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled. 2. Prior diagnosis of cancer or suspected of having cancer 3. Karnofsky performance status of greater than 70 4. Standard pretreatment evaluation 5. Signed Stanford University Human Subjects Committee consent

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood

MeSH Terms

Conditions

CarcinomaAdenocarcinomaNeoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Maximilian Diehn

    Stanford University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu

CONTACT

650-498-7757gitrialeligibility@stanford.edu

gitrialeligibility@stanford.edu

CONTACT

650-498-7757gitrialeligibility@stanford.edu

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 5, 2006

First Posted

July 10, 2006

Study Start

January 1, 2002

Primary Completion (Estimated)

January 1, 2032

Study Completion (Estimated)

January 1, 2032

Last Updated

February 10, 2026

Record last verified: 2026-02

Locations

US(1)